We found that CRC cell death caused by MLKL inactivation is enhanced by homoharringtonine (HHT), a drug used to treat chronic myelogenous leukemia [4]. The gene discussed is MLKL; the disease is chronic myelogenous leukemia, BCR-ABL1 positive.